The European Medicines Agency recommended on the 11th local time that people with a history of capillary leak syndrome should not be vaccinated against the novel coronavirus infection by AstraZeneca, a multinational pharmaceutical company.
The EMA Safety Committee concluded that people with capillary leak syndrome prior to today should not receive the AZ vaccine, and said capillary leak syndrome should be added to the product information as a new side effect of the vaccine.
Capillary Leak Syndrome is a rare but serious condition that causes fluid to leak from capillaries, causing swelling of arms and legs and low blood pressure, the EMA explained.
The EMA found that the Safety Committee conducted an in-depth review of six cases of capillary leak syndrome in people vaccinated with AZ, most of which occurred within four days of vaccination in women.
The EMA says health care workers should be aware of the signs and symptoms of this disease and seek immediate medical help if they experience rapid swelling or sudden weight gain in their arms or legs within a few days of getting the AZ vaccine.
The EMA adds that these symptoms can occur along with dizziness due to low blood pressure.
The EMA previously concluded that specific thrombus with thrombocytopenia should be included as a very rare adverse event for the AZ COVID-19 vaccine.